Flash Therapeutics, a gene therapy CDMO that develops and produces DNA and RNA transfer technologies, reports that it is accelerating the ramp-up of its biomanufacturing capabilities. This will allow the Toulouse, France-based company to position itself for the production of large-scale clinical batches, including both integrative DNA and RNA technologies (its proprietary LentiFlash® technology), according to Pascale Bouillé, president of Flash Therapeutics, who adds that an overall investment of around €15 million will be required to ensure the growth of its production capacity to GMP industrial level.

In this context, Flash Therapeutics signed a three-year investment agreement of at least €15 million with TechLife Capital and Elaia Partners. The first payment of €4 million made in July 2021 allows Flash Therapeutics to double its infrastructure over the next 12 months and to strengthen its commercial, process, analytical, and production teams, continues Bouillé.

Flash Therapeutics touts its expertise in lentiviral transfer technologies (DNA and RNA) and its biomanufacturing process and notes that it offers a continuum of high purity vector manufacturing from research to clinical phases in gene and cell therapy programs (genetic diseases, infectious diseases, cancers)  and vaccination.

“Our goal is to double in size by the second half of 2022 and to produce the first LentiFlash messenger RNA clinical batch by the end of 2022,” says Bouillé.

Previous articleMicrobiome’s Metabolism Altered by Bioaccumulation of Medications
Next articlePredicting Heart Failure Using the Plasma Proteome